ARMP Armata Pharmaceuticals Inc

Price (delayed)

$8.02

Market cap

$294.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.78

Enterprise value

$659.22M

?
Relative Growth: Rel. Growth: 0
Relative Strength: Rel. Strength: 92
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 0

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is ...

Highlights
The company's debt has surged by 177% YoY and by 30% QoQ
The company's net income has shrunk by 63% QoQ

Key stats

What are the main financial stats of ARMP

ARMP stock price

How has the Armata Pharmaceuticals stock price performed over time
Intraday
5.67%
1 week
-1.23%
1 month
-18.58%
1 year
306.08%
YTD
27.71%
QTD
-21.68%

Financial performance

How have Armata Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$42.43M
Net income
-$282.61M
Gross margin
N/A
Net margin
N/A
The company's net income has shrunk by 63% QoQ
Armata Pharmaceuticals's operating income has increased by 6% YoY but it has decreased by 2.1% QoQ

Price vs fundamentals

How does ARMP's price correlate with its fundamentals

Growth

What is Armata Pharmaceuticals's growth rate over time

Valuation

What is Armata Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Armata Pharmaceuticals's EPS has shrunk by 62% QoQ
The equity has contracted by 43% from the previous quarter

Efficiency

How efficient is Armata Pharmaceuticals business performance
Armata Pharmaceuticals's ROA has plunged by 72% from the previous quarter
ARMP's return on invested capital is down by 10% since the previous quarter

Dividends

What is ARMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARMP.

Financial health

How did Armata Pharmaceuticals financials performed over time
ARMP's total assets is 82% lower than its total liabilities
The company's total liabilities has surged by 170% YoY and by 29% QoQ
ARMP's current ratio is down by 46% since the previous quarter
The company's debt has surged by 177% YoY and by 30% QoQ
ARMP's debt to equity has soared by 52% year-on-year and by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.